Medical Educational Resource
Myositis: Updates in Diagnosis and Treatment
This Grand Rounds webinar focuses on the diagnosis and treatment of myositis. Included in this program will be an overview of the classifications and subtypes, treatment algorithms of myositis and promising treatments on the horizon.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the Muscular Dystrophy Association. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.
PeerPoint Medical Education Institute designates the live and enduring formats for this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The Live approval period is: November 29, 2022 The Enduring approval period is: December 9, 2022 – December 9, 2023
Please email email@example.com for instructions to obtain CME credit.
The following planners, speakers, reviewers or staff have relevant financial relationships to disclose:
Julie J. Paik
Pfizer Inc: Clinical Trial Support, Advisory Board; Speaker/Planner-Reviewer
Kezar Inc: Clinical Trial Support, Advisory Board; Speaker/Planner-Reviewer
Roivant: Advisory Board; Speaker/Planner-Reviewer
EMD Serono: Consultant; Speaker/Planner-Reviewer
Guidepoint Consultation: Consultant; Speaker/Planner-Reviewer
Alexion: Clinical Trial Support; Speaker/Planner-Reviewer
Uptodate: Royalties; Speaker/Planner-Reviewer
“I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies.”
These financial relationships with ineligible companies have been mitigated by PeerPoint Medical Education Institute and the Muscular Dystrophy Association.
All other presenters, planners, editors, or staff report no relationships to disclose:
“I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies.”